IONS241220C22500
- 0.00
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?
PANTHERx Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA (Olezarsen)
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
Express News | Ionis Pharmaceuticals Inc : Oppenheimer Raises Target Price to $78 From $75
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67
Sector Update: Health Care Stocks Mixed Premarket Friday
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
Express News | Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals Reports FDA Approval of Tryngolza
Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug
The rare disease drug Olezarsen under Ionis Pharmaceuticals (IONS.US) has been approved by the FDA.
The FDA has approved Olezarsen, a product of Ionis Pharmaceuticals, for the treatment of familial chylomicronemia syndrome (FCS).
Express News | Trading Halt: Halt Status Updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times
Express News | Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End
TRYNGOLZA (Olezarsen) Approved in U.S. as First-ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet
Ionis Pharmaceuticals Trading Halted, News Pending
Express News | Trading Halt: Halted at 4:28:30 P.m. ET - Trading Halt: Halt News Pending
Worst Performing Stocks for Tax Loss Selling – Wolfe